You missed your weekly GLP-1 dose — what the label actually says
By the DoseRoutine Editorial Team · · · How we review content
For once-weekly semaglutide, the label says take the missed dose within 5 days of the scheduled day; past that, skip it and resume your normal schedule. For once-weekly tirzepatide, the window is 4 days. In both cases you never double up, and if you have missed several weeks in a row you usually need to restart lower and re-titrate rather than resume your old dose.
- Semaglutide: take within 5 days of the missed day, otherwise skip.
- Tirzepatide: take within 4 days, otherwise skip.
- Never take two doses to compensate — nausea and vomiting scale with dose, not with adherence.
- Missing more than about two consecutive weeks usually means restarting at a lower dose to rebuild tolerance.
- You can change your fixed weekly day as long as at least 72 hours separates two doses.
The windows, and why they differ
Both drugs are engineered for a long half-life so that plasma levels stay reasonably flat across a week. The missed-dose windows reflect how far a level can drift before a full dose becomes a relative spike. Semaglutide's longer half-life buys a slightly wider window than tirzepatide's, which is the whole reason one label says five days and the other says four.
If more days than that have passed, the correct action is simply to skip and take the next scheduled dose. One missed week does not undo months of treatment.
When you need to re-titrate instead of resume
Gastrointestinal tolerance is built during dose escalation and it decays when exposure stops. After a gap of a few weeks — a supply issue, travel, a hospital stay — resuming at your previous dose is the most common cause of a miserable week of nausea and vomiting. Restarting one or two steps down and moving back up over a few weeks is the standard approach, and it is worth confirming with your prescriber rather than guessing.
Moving your injection day
Changing the day of the week is allowed as long as there are at least 72 hours (3 days) between consecutive doses. In practice, pick the day you are most likely to be at home and settled, then keep it fixed. A recurring reminder tied to that day removes the entire problem, and a dose log tells you immediately whether Tuesday's injection actually happened or you only remember intending it.
What not to do
- Do not take two doses on the same day or within 72 hours.
- Do not increase the next dose to 'catch up' on lost progress.
- Do not resume a high dose after a multi-week gap without re-titrating.
- Do not switch products mid-titration without prescriber guidance — the dose steps are not interchangeable.
This is a summary of published research for general information. Investigational drugs are not available outside clinical trials, and research chemicals sold online are not the same products. Talk to a clinician who knows your history and labs before changing anything you take.
Frequently asked questions
How late can I take a missed semaglutide dose?
Up to 5 days after the scheduled day. Beyond that, skip the missed dose entirely and take the next one on your regular day. Do not take two doses close together.
How late can I take a missed tirzepatide dose?
Up to 4 days after the scheduled day, according to the tirzepatide label. If more than 4 days have passed, skip the missed dose entirely and take the next one on your normal weekly day. Never take two doses within 72 hours of each other to catch up.
What happens if I miss two or three weeks?
Tolerance to gastrointestinal side effects fades within a few weeks off the drug, so restarting at your previous dose often causes significant nausea and vomiting. Most prescribers restart one or two dose steps lower and re-escalate on the usual four-week schedule. After roughly three or more missed weeks, ask before resuming.
Can I change my injection day?
Yes. Both the semaglutide and tirzepatide labels allow you to change your injection day, provided at least 72 hours separate the last dose and the first dose on the new day. After the switch, keep the new day fixed so your weekly interval stays consistent.
Will one missed dose cause weight regain?
A single missed week has minimal effect. Sustained discontinuation is a different matter — in the semaglutide withdrawal extension, participants regained roughly two-thirds of lost weight within a year of stopping.
Where to track this
- the best GLP-1 tracking apps compared for 2026 — How dose logging, titration history and side-effect notes differ across apps.
- how DoseRoutine handles GLP-1 protocols week to week — Weekly shot reminders, titration steps and missed-dose handling.
- tracking peptides, supplements and hormones in one place — Why a single timeline beats three separate apps when protocols overlap.
Related guides & tools
Matched to the compounds and mechanisms covered in this update.
Related updates
Other posts covering the same compounds, mechanisms and trial phases.
Keep reading
About the author
DoseRoutine Editorial Team — Maintainers of the DoseRoutine compound library and interaction rule set
The DoseRoutine Editorial Team maintains the compound library and the interaction rule set behind DoseRoutine.
We summarize published trials, regulatory documents (FDA, EMA) and company announcements into plain-English updates. Every factual claim on a post is tied to a linked source below.
Posts are written and reviewed by the editorial team, not by a licensed clinician. This is educational reference content — it never recommends an amount for you to take.
Sources & references
3 sources — primary literature, regulatory documents and company announcements, each linked to the original document. Last reviewed . How we select and review sources.
- ReferenceMedlinePlus. Semaglutide injection — patient drug information, missed dose and storage guidance. View source on medlineplus.gov
- RegulatoryDailyMed. Prescribing information labels for tirzepatide injection products (Mounjaro, Zepbound). View source on dailymed.nlm.nih.gov
- Peer-reviewedWilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553–1564. View source on pubmed.ncbi.nlm.nih.gov